Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$1,097 Mln
P/E Ratio
--
P/B Ratio
103.11
Industry P/E
--
Debt to Equity
9.2
ROE
-1.57 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-13.54
CFO
kr-1,888.33 Mln
EBITDA
kr-2,030.69 Mln
Net Profit
kr-2,183.85 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Calliditas Therapeutics AB (CALT)
| 55.38 | -0.87 | 4.25 | 118.97 | 21.29 | -- | -- |
|
BSE Sensex*
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
2023
|
2022
|
2021
|
|
|---|---|---|---|
|
Calliditas Therapeutics AB (CALT)
| 51.44 | -31.34 | -26.35 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant... unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. As of September 13, 2024, Calliditas Therapeutics AB (publ) operates as a subsidiary of Asahi Kasei Corporation. Read more
Chief Executive Officer
Ms. Renee Aguiar-Lucander
Chief Executive Officer
Ms. Renee Aguiar-Lucander
Headquarters
Stockholm
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Calliditas Therapeutics AB (CALT) stood at $ 2,177 Mln as on 30-Jun-24
The share price of Calliditas Therapeutics AB (CALT) is $40.00 (NASDAQ) as of 27-Sep-2024 09:30 EDT. Calliditas Therapeutics AB (CALT) has given a return of 21.29% in the last 3 years.
Calliditas Therapeutics AB (CALT) has a market capitalisation of $ 1,097 Mln as on 27-Sep-2024. As per Value Research classification, it is a company.
The P/B ratio of Calliditas Therapeutics AB (CALT) is 103.11 times as on 27-Sep-2024, a 4403% premium to its peers’ median range of 2.29 times.
Since, TTM earnings of Calliditas Therapeutics AB (CALT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Calliditas Therapeutics AB (CALT) and enter the required number of quantities and click on buy to purchase the shares of Calliditas Therapeutics AB (CALT).
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. As of September 13, 2024, Calliditas Therapeutics AB (publ) operates as a subsidiary of Asahi Kasei Corporation.
The CEO & director of Ms. Renee Aguiar-Lucander. is Calliditas Therapeutics AB (CALT), and CFO & Sr. VP is Ms. Renee Aguiar-Lucander.
There is no promoter pledging in Calliditas Therapeutics AB (CALT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Calliditas Therapeutics AB (CALT) | Ratios |
|---|---|
|
Return on equity(%)
|
-217.56
|
|
Operating margin(%)
|
-23.02
|
|
Net Margin(%)
|
-30
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Calliditas Therapeutics AB (CALT) was $-168 Mln.
